Introduction
Over the past decade, research has been focused on the mechanisms through which various types of neoplasms might take a more malignant phenotype and form more aggressive cell clones which can determine tumor development and progression. It is well known that the rapid proliferation of malignant cells causes the formation of hypoxic areas within the stroma of solid human tumors [
1]. Hypoxia is able to induce many changes in the physiological processes and biochemistry of malignant cells by upregulating the expression of a number of target genes,
inter alia those related to glucose metabolism and glucose transport, angiogenesis, invasion, and metastasis, in order to adapt to anaerobic conditions [
1‐
5]. The results of many studies have provided evidence of the carcinogenic effects of the inhibition of the oxidative phosphorylation process and conversion into enhanced aerobic glycolysis, known as the Warburg effect, which is associated with the activity of key factors in glucose metabolism like glucose transporters (GLUTs) and their most important regulatory hypoxia-related protein, hypoxia-inducible factor-1α (HIF-1α) [
6].
Until now, 14 members of the GLUT family coded by genes belonging to the solute carrier 2A family (
SLC2A) have been identified [
7]. Numerous in vivo and in vitro studies suggest that the biological activity of GLUT isoforms and their participation in many regulatory mechanisms involving, among others, the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, NF-κB activity, and wild-type p53 protein expression may contribute to cancer development [
8‐
11]. GLUTs also promote the epithelial-mesenchymal transition (EMT), cell migration, invasion, and metastasis by the regulation of matrix metalloproteinase (MMP) activity [
12]. Other mechanisms of carcinogenesis are HIF-1α activity in EMT via the inhibition of E-cadherin and promotion of MMP-2 and SNAI1 expression, the regulation of the PI3K/Akt pathway, as well as VEGF activation [
3,
4,
13,
14].
A literature review reveals the contribution of aberrant various glucose uptake transporter isoforms and metabolism/hypoxia regulators to the tumorigenesis and progression of various head and neck cancers [
8,
15‐
22]. Unfortunately, the clinical importance of alternations in glucose metabolism and GLUT expression in these malignances is largely unknown. Most reviews focus on the association between cellular level of GLUTs and both tumor aggressiveness and disease outcome [
8,
15‐
22]. Unfortunately, other studies have reported not only contradictory results and inverse interconnections, but also a lack of any association between the expression of metabolism/hypoxia endogenous markers with either clinicopathological tumor features or patient prognosis [
23‐
26].
Despite conflicting data, research reveals that the identification of changes in cancer metabolism reprogramming based on GLUT isoform expression, as well as the oncogenic mechanisms leading to increased aerobic glycolysis, may be considered as potential new therapeutic targets for treatment strategies. They may also be used in synergy with conventional treatments to alter and/or inhibit cancer invasiveness and progression. Therefore, many authors propose the suppression of
SLC2A1 and
SLC2A3 genes by the use of antisense oligodeoxynucleotides which decrease glucose uptake, inhibit the proliferation of malignant cells, and enhance of radiosensitivity and chemosensitivity. This in turn allows the optimal treatment modality of neoplastic lesions, between them cancers of the head and neck region [
12,
27,
28].
Less controversy surrounds the expression of HIF-1α, the endogenous regulator of glucose metabolism mechanisms in hypoxia conditions, with regard to clinicopathological parameters in various types of head and neck neoplasms. Previous studies indicate that cancer cells appear to display overexpression of this metabolic hypoxia-related protein in most tumor cases, and a high HIF-1α level is related to an enhanced grade of tumor aggressiveness, higher incidences of metastasis, and poor prognosis [
26,
29‐
31]. However, a literature review reveals the conflicting results related to HIF-1α expression and its relationship with clinical features in various neoplastic lesions [
4,
32,
33].
Unfortunately, it is hard to find literature data which clearly demonstrates the clinical importance of the relationship between HIF-1α level and GLUT isoform activity, as well as a precise multifactorial histological estimation of their influence on neoplastic aggressiveness in head and neck cancers. Hence, more studies are needed to elucidate the biological functions of both GLUTs and regulatory molecule HIF-1α in the carcinogenic process, and their possible clinical significance as parameters of tumor invasiveness and prognostic factors in this type of neoplasm.
The aim of this study was to determine the messenger RNA (mRNA) expression of SLC2A1 and SLC2A3 genes coding GLUT isoform 1 (GLUT1) and isoform 3 (GLUT3), as well as the regulatory HIF-1α gene and the levels of their corresponding proteins, to investigate their influence on tumor aggressiveness and patient prognosis in squamous cell laryngeal cancer.
Discussion
In the last decade, a growing body of evidence indicates that increased level of glycolytic activity observed under aerobic conditions (the Warburg effect) needed to meet the energy requirements of tumor cells and the endogenous markers of metabolism/hypoxia may contribute to the development, proliferation, angiogenesis, and progression of various types of head and neck cancers [
1‐
5]. Studies have linked GLUT function to cancer cell dynamics and tumor pathology, yet findings remain limited and often divergent, especially regarding the impact of their specific isoforms on tumor invasion and prediction of patient outcome [
15‐
26]. The activity of the glycolytic pathway may also be responsible for radioresistance and chemoresistance and thus may affect patient prognosis [
27,
28,
37].
Our study documents for the first time the relationship between the expression of GLUT1 and GLUT3 isoforms in the fresh human biopsy material and the dynamics of tumor growth in laryngeal cancer, according to a precise, multifactorial histological analysis of tumor front aggressiveness. Importantly, the material studied constitutes a homogeneous and numerous groups of head and neck cancers sharing the same origin. This composition of the study groups adds to the value of this research, when the difficulties in obtaining fresh human biopsy tissues such as cancerous and matched normal tissues are taken into consideration. It should be also noted that, due to these difficulties, the overwhelming majority of previous studies have used cell cultures and paraffin-embedded archival material, often also limited in number, which doubtlessly have an impact on the final results. In this study, the protein expression in less material due to this limitation complements research on the genes studied.
A literature search indicates that no studies on the amplification of the SLC2A1 and SLC2A3 genes in fresh tissues from the head and neck region have yet been performed. Since copies of the studied genes were found in only 2 % cases of laryngeal carcinoma, it can be concluded that SLC2A1 and SLC2A3 amplification does not affect the expression of GLUT1 and GLUT3 in this type of neoplasm.
The resulting data concerning expression of GLUT isoforms in laryngeal cancer resembles the findings of other researchers [
28,
38‐
40]. However, it should be noted that a literature survey revealed only a few studies on these relationships in head and neck cancer. For instance, Zhou et al. [
22] reported that the expression of the GLUT1 and GLUT3 genes were significantly higher in cancerous tissue than in adjacent normal tissue in 38 head and neck cancer samples. A similar result was reported by Burstein et al. [
38] for 27 cases of squamous intraepithelial neoplasia and 26 invasive carcinomas of the head and neck region. In this study, upregulation of GLUT1 at the protein level was established in tumor specimens compared with normal epithelium, characterized by negativity or weak/equivocal staining. Previous studies have also reported a lower prevalence or absence of HIF-1α in noncancerous tissue of various head and neck tumors [
39,
40]. For example, Zhang et al. [
39] observed an overexpression of both GLUT1 and HIF-1α proteins in 85 neoplastic tissues of oral squamous cell cancer and conclude these metabolism/hypoxia-related proteins can be predictive markers for malignant conversion of oral premalignant epithelial dysplasia. Similarly, Xie et al. [
40] confirmed enhanced immunostaining for HIF-1α in 56 laryngeal cancer tissues and its negative expression in normal mucosa specimens.
In addition, a literature review reveals a wide range of findings concerning expression rate and distribution of GLUTs in various head and neck cancers. The data concerning the expression of GLUT1 and GLUT3 transcripts or, most often, protein immunoexpression identified in laryngeal cancer cases were found to be very similar to ours: the mean frequency of GLUT1 was in the range 50.3–98 % while GLUT3 positive expression was less so [
8,
18,
21,
22,
24‐
26]. The reasons for lower GLUT3 mRNA/protein expression in various cancer specimens may be, on the one hand, the activity of other GLUT isoforms, i.e., GLUT1, which are responsible for the glucose uptake and glycolytic metabolism, and on the other hand, due to heterogeneity of GLUT expression within tumor tissues. In addition, laryngeal cancers often have numerous foci of necrosis, where glucose metabolism is less pronounced and may result in lower expression of the less active GLUT3 isoform [
41]. Therefore, our analysis has been restricted to areas without tumor necrosis. It is not without significance that HIF-1α activity, which determines GLUT expression, is also not ubiquitous and heterogenous in cancerous tissue and increases with the distance of the sampling site from the blood vessels [
42].
Studies have confirmed the role of GLUT isoforms, mainly GLUT1, in head and neck neoplastic lesions and both cancer development, tumor progression and patient prognosis, but many demonstrate equivocal and divergent results [
15‐
26]. Importantly, most which address invasive behavior concern only standard clinical parameters (TNM classification, grade) and survival time.
Most studies confirm the increased expression of GLUTs in more advanced head and neck cancers, where a positive association was found for clinical variables including tumor grade and stage [
8,
18,
22,
26,
43]. For instance, Wu et al. [
8] reported enhanced GLUT1 isoform expression in a studied population of 49 laryngeal cancer cases and identify a positive association between GLUT1 immunostaining and primary tumor site, lymph node invasion, and recurrences. Similarly, Ayala et al. [
18] estimated a positive association of GLUT3 immunoexpression with advanced clinical tumor stage and vascular embolization in laryngeal cancer. Kondo et al. [
26] also revealed a correlation between increased GLUT1 IHC expression in primary oral cancer tissues with advanced nodal metastatic stage but, as identified by the present study, not with the survival rate. Zhou et al. [
22] indicated that higher GLUT1 and GLUT3 mRNA levels in head and neck carcinomas may also have an effect on advanced clinical stage and positive lymph node status. The distributions of hypoxia/metabolic markers in oral tongue cancer described by Roh et al. [
43] confirm those given in the present study. The researchers suggest that GLUT1 expression contributes to tumor thickness and nodal classification. Also, Demasi et al. [
19] revealed that overexpression of GLUT1 corresponds to lower histological tumor differentiation in patients with salivary gland carcinoma, which confirms our results. Ciampi et al. [
21] performed an analysis of GLUT expression in human thyroid primary carcinoma tissues and cell lines to determine the impact of GLUT1 on tumor histological differentiation. The authors note that the occurrence of positive GLUT1 expression is frequently characteristic of anaplastic tumors compared with well-differentiated cancers. By contrast, overexpression of GLUT3 mRNA in this cell cancer model corresponds to lower tumor grade. It was also determined that the protein level of this isoform in fresh tissue samples is not detectable. However, Ohba et al. [
20] suggest that upregulation of GLUT1 protein level may play a crucial role in determining the depth of invasion but bears no relation with primary tumor size and nodal metastases in oral carcinoma.
Nevertheless, contrary results for GLUT1 and GLUT3 immunoexpression related to such clinical parameters as primary tumor size, extrathyroidal extension, and lymph node metastases has also been reported by Kaida et al. [
23]. This data is confirmed by Kwon et al. [
37] in a study of 42 early-stage laryngeal cancers, which notes that GLUT1 was not found to exert any influence on residual tumor or survival after radiotherapy. Subsequently, no association between GLUT1 level in malignant oesophageal cancer samples and pN stage was shown by Kobayashi et al. [
16]. However, similar to our results, the authors reported enhanced GLUT1 immunostaining in individuals with more locally advanced carcinomas in this region of the head and neck.
Unfortunately, the relationship between GLUT level and prognosis was also found to be divergent in the head and neck cancer populations. The obtained data confirms that GLUT isoform expression was unrelated to mortality. The prognosis results described by Müssig et al. [
25] were almost the same as those given in the present study. Higher GLUT1 immunoexpression has been found not to be associated with clinical outcome in the thyroid cancer population. Similarly, Schrijvers et al. [
44] reported different findings regarding GLUT1 immunostaining in 91 early-stage glottic carcinomas treated with radiotherapy only. In this case, GLUT1 overexpression was found to be not significantly related to the clinical outcome parameters.
However, other researchers report different findings and conclude that GLUT activity may be implicated in patient survival time. For instance, Ohba et al. [
20] suggested that upregulation of GLUT1 protein level may affect prognosis in patients with oral carcinoma. Similarly, Zhou et al. [
22] observed that individuals having GLUT1 positive gene expression demonstrated considerably shorter overall survival, but no association was found between GLUT3 transcript and prognosis in the studies head and neck cancer populations.
Less controversy and fewer conflicting results concern the clinical and prognostic value of HIF-1α and its relationship with glucose metabolism molecules in head and neck cancers [
8,
45]. Our study shows a strong positive correlation between the activity of HIF-1α and GLUT1, but not GLUT3, and indicates its association with a higher advancement of neoplastic lesions and poor patient outcome. The literature also offers a considerable body of evidence for the role of HIF-1α in carcinogenesis and the metabolic regulation of GLUTs, thus confirming our observations. For example, Wu et al. [
8] demonstrated a significant correlation between HIF-1α and GLUT1 expression and report that increased hypoxia/metabolism markers are independent predictors of recurrences, lymph node metastases, and shortened survival in laryngeal cancer. Similarly, Yamada et al. [
45] confirmed the significant coexpression of HIF-1α and GLUT1 in early-stage tumors in squamous cell oral cancers.
A few studies concerning HIF-1α expression in relation to tumor behavior and prognosis in head and neck carcinomas also confirm our findings [
29‐
31]. Li et al. [
31] reported that HIF-1α could be regarded as a potential predictor of a higher clinical stage and nodal metastases of laryngeal carcinoma. Also, Koperek et al. [
30] suggested that HIF-1α contributes to a higher pN status and peritumoral/extrathyroidal infiltration, as well as angioinvasion in thyroid carcinoma. Ping et al. [
29] noted that HIF-1α overexpression was found to be significantly related to stage, nodal metastases, depth of invasion, local recurrences, and clinical outcome in esophageal cancer.
Unfortunately, a few studies present inconsistent data regarding the status of HIF-1α as a biomarker of tumor invasiveness and prognosis [
32,
33]. For example, Douglas et al. [
32] noted a lack of prognostic effect of HIF-1α overexpression in patients with early squamous cell carcinoma of the glottis treated with radiotherapy. Also, Cabanillas et al. [
33] observed that HIF-1α expression correlated with the tumor local extension but was not associated with tumor stage or lymph node metastases in supraglottic laryngeal cancer.
Finally, it should be also stressed that there are limitations to our study. While GLUT1 and GLUT3 expression could be considered as useful potential biomarkers for tumor behavior in laryngeal cancer, discrepancies exist for other tumors of this region due to variation of tumor types, histological differentiation status, and proliferative index, which cause differences in their biology. Admittedly, the results indicate the issue role of GLUTs and interactions with HIF-1α as their key regulator in cancers, but it is not clearly understood and there is a need for future research to clarify the relevance of GLUT proteins in carcinogenicity and the behavior of various tumors. Also, because of the limited amount of biological material in our study, GLUTs and HIF-1α were compiled with regard to protein expression only, with pTNM classification, the currently accepted prognostic parameters, being used in a smaller number of laryngeal cancer cases.